Nearing Finish Line, HCV Race Focuses On Salvage Therapy

Nov 24 2016

Listen to this article

With few remaining unmet needs in hepatitis C, Gilead, Merck and AbbVie are focusing on tough-to-treat niches with their next-gen combination regimens, especially treatment-experienced patients who failed on prior direct-acting antiviral therapy. Merck also is studying injectable drug users in an effort to eradicate HCV entirely.

BOSTON – Change was in the air at the American Association for the Study of Liver Diseases meeting here Nov. 11-15 and not just because of the recent US election results. The shifting drug development focus in liver diseases from the hepatitis C virus (HCV) to non-alcoholic steatohepatitis (NASH) is palpable, with market-leader Gilead Sciences Inc. recently stating that its latest Phase III, three-drug combination regimen probably signals the end of its R&D work in HCV.

Still, Gilead and its two closest pursuers in HCV – Merck & Co. Inc. and AbbVie Inc. –...

Scrip Data Article Without An Author

Nov 19 2025

"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."

In Brief: PolyPid’s D-PLEX100 Aces Phase III Trial, US Partner, Submission Eyed

Nov 02 2025

PolyPid's D-PLEX100 meets Phase III endpoints this time around, significantly reducing surgical point infections in abdominal colorectal surgery, and is set for a US approval submission early next year.